


## SUPPLEMENTARY MATERIAL

### Supplementary material 1. Flow-chart of patients' selection



### Supplementary material 2.

Comparison between MuSK-MG patients detected by CBA and RIA-positive MuSK-MG

	MUSK CBA+ N=7	MUSK RIA+ N=103	p
Median age at onset (IQR), years	40 (45)	38 (26)	0.5443
Female	5/7 (71%)	81/103 (79%)	0.645
Ocular MG	4/7 (57%)	0/103	<b>&lt;0.001</b>
Max. disease severity			
ocular	4/7 (57%)	0/103	<b>&lt;0.001</b>
mild	3/7 (43%)	9/103 (9%)	<b>0.0275</b>
moderate	0/7	52/103 (50%)	<b>0.0137</b>
severe	0/7	14/103 (14%)	0.5921
crisis	0/7	28/103 (27%)	0.1877
bulbar	2/7 (29%)	101/103 (98%)	<b>&lt;0.001</b>
Treatment			
No IS	1/7 (14%)	3/103 (3%)	0.2342
CS	4/7 (57%)	34/103 (33%)	0.2316
CS+IS	2/7 (29%)	66/103 (64%)	0.1034
Median follow-up (IQR), years	10 (13.5)	10 (14)	0.4925

**Supplementary material 3.**

Comparison between clustered AChR-MG and the AChR-RIA positive population

	Clustered AChR+ N=16	RIA AChR+ n=200	p
Median age at onset (IQR), years	39 (29-53)	52 (34.5-67.5)	<b>0.0002</b>
Female	7/16 (44%)	102/200 (51%)	0.746
Max. disease severity			
ocular	7/16 (44%)	24/200 (12%)	<b>0.003</b>
mild	5/16 (31%)	62/200 (32%)	1.000
moderate	4/16 (25%)	80/200 (40%)	0.2937
severe	0/16	9/200 (4.5%)	1.000
crisis	0/16	25/200 (12.5%)	0.2264
bulbar	2/16 (13%)	104/200 (52%)	<b>0.003</b>
Treatment			
No IS	7/16 (44%)	33/200 (16.5%)	<b>0.0141</b>
CS	6/16 (37%)	75/200 (37.5%)	1.000
CS+IS	3/16 (19%)	92/200 (46%)	<b>0.0384</b>
Thymectomy	3/16 (19%)	100/200 (50%)	<b>0.019</b>
Median follow-up (IQR), years	15 (6-19)	7 (3-12)	<b>0.0368</b>
PIS: MM-or-better	10/16 (63%)	139/200 (69.5%)	0.58

**Supplementary material 4.**

Comparison between triple SNMG and the AChR-RIA positive population

	tSNMG n=59	RIA AChR+ n=200	p
Median age at onset (IQR), years	39 (29-53)	52 (34.5-67.5)	<b>0.0002</b>
Female	39/59 (66%)	102/200 (51%)	<b>0.041</b>
Max. disease severity			
ocular	19/59 (32%)	24/200 (12%)	<b>0.0006</b>
mild	23/59 (39%)	62/200 (32%)	0.2511
moderate	14/59 (24%)	80/200 (40%)	<b>0.0224</b>
severe	1/59 (2%)	9/200 (4.5%)	1.000
crisis	2/59 (3%)	25/200 (12.5%)	0.0514
bulbar involvement	18/59 (31%)	104/200 (52%)	<b>0.004</b>
Treatment			
No IS	23/59 (39%)	33/200 (16.5%)	<b>0.0002</b>
CS	26/59 (44%)	75/200 (37.5%)	0.3634
CS+IS	10/59 (17%)	92/200 (46%)	<b>&lt;0.0001</b>
Thymectomy	12/59 (20%)	100/200 (50%)	<b>&lt;0.0001</b>
Median follow-up (IQR), years	12 (5-18)	7 (3-12)	<b>0.0012</b>
PIS: MM-or-better	39/59 (65%)	139/200 (69.5%)	0.621

AChR= acetylcholine receptor; CS= corticosteroids; IQR=interquartile range; MG= myasthenia gravis; MGFA=myasthenia gravis foundation of America; MM= minimal manifestation; MuSK= muscle tyrosin-kinase; IS=immunosuppressants; PIS= post intervention status; tSNMG= triple seronegative myasthenia gravis.